Impact Assessment Summary
|Factors ||Initial Effect ||Expected 1yr Recovery ||Comments |
|Company Sales/Revenue ||Moderate ||Moderate ||Delays in procedures and adverse economic impact will result in facilities delaying the purchase of new systems. |
|Procedure Volumes ||Moderate ||Moderate ||The majority of imaging procedures have been postponed, except for chest CT and X-ray in COVID-19 patients |
|ASPs ||Moderate ||Moderate ||Most manufacturers in this space depend on China for raw materials; companies may have to contend with increased production costs until the situation stabilizes. |
|New Product Launches ||Weak ||Weak ||Early-stage innovation will slow, whereas products in late stages of development should launch as scheduled. |
|Supply Chain ||Moderate ||Moderate ||Most manufacturers depend on China for raw materials; though supply chain disruptions were observed in Q1, these are not expected to have a substantial impact on large imaging companies. |
*General guidance: Weak: 0-10% change in values/timelines; Moderate: 10-20% change in values/timelines; Strong: >20% change in values/timelines. DRG Medtech is developing a robust quantitative framework for our market forecasts; impact metrics shown he re may change in the future to align with those used in the quantitative framework.